Odabas, H. Et Al. 2011. First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab. Journal of B.U.ON. , vol.16, no.2 , 247-252.

Odabas, H., Ozdemir, N., Abali, H., Oksuzoglu, B., Isik, M., Uncu, D., ... Cihan, S.(2011). First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab. Journal of B.U.ON. , vol.16, no.2, 247-252.

Odabas, H. Et Al. "First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab," Journal of B.U.ON. , vol.16, no.2, 247-252, 2011

Odabas, H. Et Al. "First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab." Journal of B.U.ON. , vol.16, no.2, pp.247-252, 2011

Odabas, H. Et Al. (2011) . "First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab." Journal of B.U.ON. , vol.16, no.2, pp.247-252.

@article{article, author={H. Odabas Et Al. }, title={First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab}, journal={Journal of B.U.ON.}, year=2011, pages={247-252} }